array:24 [ "pii" => "S2444382423000950" "issn" => "24443824" "doi" => "10.1016/j.gastre.2022.08.004" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "1979" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2023;46:377-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210570522002114" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2022.08.007" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "1979" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2023;46:377-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta científica</span>" "titulo" => "Eficacia, persistencia y optimización de ustekinumab en colitis ulcerosa: datos de práctica clínica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "377" "paginaFinal" => "379" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy, persistence and optimization of ustekinumab in ulcerative colitis: Clinical practice data" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Irene Latras-Cortés, Patricia Suárez Álvarez, María García Prada, Noelia Cano Sanz, Luis Vaquero Ayala, Mónica Sierra-Ausín" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Irene" "apellidos" => "Latras-Cortés" ] 1 => array:2 [ "nombre" => "Patricia" "apellidos" => "Suárez Álvarez" ] 2 => array:2 [ "nombre" => "María" "apellidos" => "García Prada" ] 3 => array:2 [ "nombre" => "Noelia" "apellidos" => "Cano Sanz" ] 4 => array:2 [ "nombre" => "Luis" "apellidos" => "Vaquero Ayala" ] 5 => array:2 [ "nombre" => "Mónica" "apellidos" => "Sierra-Ausín" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2444382423000950" "doi" => "10.1016/j.gastre.2022.08.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423000950?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570522002114?idApp=UINPBA00004N" "url" => "/02105705/0000004600000005/v2_202306121243/S0210570522002114/v2_202306121243/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2444382423000925" "issn" => "24443824" "doi" => "10.1016/j.gastre.2021.12.010" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "1900" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Gastroenterol Hepatol. 2023;46:380-1" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Image of the month</span>" "titulo" => "Portal hypertension due to hyperflow: splenic arteriovenous fistula" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "380" "paginaFinal" => "381" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hipertensión portal por hiperaflujo: fístula arterio-venosa esplénica." ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 865 "Ancho" => 950 "Tamanyo" => 79317 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Abdominal CT scan. Cross-sectional slice. Abundant ascites (arrow). Enlarged spleen with heterogeneous density, showing hypo-attenuated areas suggestive of infarction (star). Splenic artery with distal aneurysmal dilation, associated with an image suggestive of an arteriovenous fistula (apparent communication and early filling of the splenic vein) (circle).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana María Bravo-Aranda, Isabel Pinazo-Martínez, Rocío González-Grande, Jesús de la Cruz-Lombardo, Miguel Jiménez Pérez" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Ana María" "apellidos" => "Bravo-Aranda" ] 1 => array:2 [ "nombre" => "Isabel" "apellidos" => "Pinazo-Martínez" ] 2 => array:2 [ "nombre" => "Rocío" "apellidos" => "González-Grande" ] 3 => array:2 [ "nombre" => "Jesús" "apellidos" => "de la Cruz-Lombardo" ] 4 => array:2 [ "nombre" => "Miguel" "apellidos" => "Jiménez Pérez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210570521003277" "doi" => "10.1016/j.gastrohep.2021.12.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570521003277?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423000925?idApp=UINPBA00004N" "url" => "/24443824/0000004600000005/v2_202311101339/S2444382423000925/v2_202311101339/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2444382423000937" "issn" => "24443824" "doi" => "10.1016/j.gastre.2022.06.007" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "1960" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2023;46:376-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Pancreatic metastasis from sarcoma, an infrequent finding" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "376" "paginaFinal" => "377" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Metástasis pancreática de sarcoma, un hallazgo infrecuente" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 364 "Ancho" => 1005 "Tamanyo" => 48778 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">a) Axial PET/CT image with pathological uptake in the body of the pancreas (SUV<span class="elsevierStyleInf">max</span> 6.14). b) Axial CT image with lesion in the body of the pancreas and dilation of the main pancreatic duct.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Daniel Aparicio-López, Jorge Chóliz-Ezquerro, Carlos Hörndler-Algárate, Mario Serradilla-Martín" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Daniel" "apellidos" => "Aparicio-López" ] 1 => array:2 [ "nombre" => "Jorge" "apellidos" => "Chóliz-Ezquerro" ] 2 => array:2 [ "nombre" => "Carlos" "apellidos" => "Hörndler-Algárate" ] 3 => array:2 [ "nombre" => "Mario" "apellidos" => "Serradilla-Martín" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210570522001662" "doi" => "10.1016/j.gastrohep.2022.06.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570522001662?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423000937?idApp=UINPBA00004N" "url" => "/24443824/0000004600000005/v2_202311101339/S2444382423000937/v2_202311101339/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Efficacy, persistence and optimization of ustekinumab in ulcerative colitis: Clinical practice data" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "377" "paginaFinal" => "379" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Irene Latras-Cortés, Patricia Suárez Álvarez, María García Prada, Noelia Cano Sanz, Luis Vaquero Ayala, Mónica Sierra-Ausín" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Irene" "apellidos" => "Latras-Cortés" "email" => array:1 [ 0 => "irenelatrascortes@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Patricia" "apellidos" => "Suárez Álvarez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "María" "apellidos" => "García Prada" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Noelia" "apellidos" => "Cano Sanz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "Luis" "apellidos" => "Vaquero Ayala" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Mónica" "apellidos" => "Sierra-Ausín" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Aparato Digestivo, Complejo Asistencial Universitario de León, León, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Complejo Asistencial Universitario de León, León, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eficacia, persistencia y optimización de ustekinumab en colitis ulcerosa: datos de práctica clínica" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Ustekinumab is a monoclonal antibody which was approved by the Food and Drug Administration for the treatment of moderate-to-severe ulcerative colitis in October 2019. As yet, there are therefore relatively few studies in clinical practice.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The main aim of this study was to determine the efficacy (clinical and biological remission), the percentage of persistence with the drug, and the need for dose optimisation.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Clinical remission is defined as a partial Mayo score <2 and no sub-index >1; biological remission, as faecal calprotectin (FC) values <150 mg/kg.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The secondary objective was to determine the efficacy of ustekinumab in joint manifestations associated with ulcerative colitis.</p><p id="par0025" class="elsevierStylePara elsevierViewall">This was a retrospective, observational study of a database maintained prospectively in the Inflammatory Bowel Disease Unit at our centre on patients who started ustekinumab from July 2018 to September 2021 (<span class="elsevierStyleItalic">N</span> = 16).</p><p id="par0030" class="elsevierStylePara elsevierViewall">A descriptive statistical analysis was performed using the IBM® SPSS® software, version 26, with statistical significance being <span class="elsevierStyleItalic">p</span> < 0.05. The qualitative variables are expressed as absolute numbers and percentages. Quantitative variables are expressed as means and standard deviation or medians and interquartile range, as appropriate. The non-parametric Friedman test was used to check for statistically significant differences in the values of the variables analysed during the clinical course.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The baseline characteristics of the patients and the disease are summarised in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">The mean treatment time with ustekinumab was 17.81 months (standard deviation 12.57) and 81.30% of the subjects started ustekinumab without concomitant corticosteroids. In two patients (12.50%), both previously treated with more than two lines of biological drugs, combination therapy with an immunosuppressant (tacrolimus) was used as induction until clinical remission was achieved (one patient for three months and the other for one month, discontinued due to neurotoxicity).</p><p id="par0045" class="elsevierStylePara elsevierViewall">Steroid-free clinical remission was achieved in 25% at week 4, 50% at week 8, 69.2% at week 16, 54.5% at week 24, 90% at week 52 and 87.5% at 18 months.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Rectal bleeding, present at baseline in 81.30% of the subjects, disappeared in half of them at week 4.</p><p id="par0055" class="elsevierStylePara elsevierViewall">There was a statistically significant decrease in the partial Mayo score during follow-up (<span class="elsevierStyleItalic">p</span> = 0.000). The median baseline FC was 1459 mg/kg (interquartile range 1911.5) with figures tending to return to normal (<span class="elsevierStyleItalic">p</span> = 0.064); the decrease occurred primarily after week 16. Biological remission was achieved in 56.25% at the end of follow-up.</p><p id="par0060" class="elsevierStylePara elsevierViewall">In 11 patients (68.75%), treatment was optimised every four weeks due to loss of secondary response or partial response. Of these, steroid-free clinical remission was achieved in 86.6% and biological remission in 45.45%. The need for optimisation seemed to be more common in the subgroup of patients with two or more prior biological drugs (77.77%) compared to patients who were naïve to (bio-naïve)/had only taken one biological drug (57.14%) (<span class="elsevierStyleItalic">p</span> = 0.596).</p><p id="par0065" class="elsevierStylePara elsevierViewall">Fourteen of the 16 patients (87.5%) who started ustekinumab were still on the treatment at the end of follow-up. In the two remaining subjects, it was necessary to change the therapeutic target (both to tofacitinib) due to loss of response and the development of <span class="elsevierStyleItalic">de novo</span> arthritis.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Data were compared according to the two groups of previous treatments: subjects with failure to ≥2 biological drugs (<span class="elsevierStyleItalic">n</span> = 9) or failure to one biological drug/bio-naïve (<span class="elsevierStyleItalic">n</span> = 7). There were differences in the mean time since onset (17.02 <span class="elsevierStyleItalic">vs</span> 6.91 years respectively; <span class="elsevierStyleItalic">p</span> = 0.021) and in the percentage of baseline rectal bleeding (100% <span class="elsevierStyleItalic">vs</span> 62.50%; <span class="elsevierStyleItalic">p</span> = 0.05). In addition, there were differences in the mean baseline partial Mayo score (7.13 <span class="elsevierStyleItalic">vs</span> 4.38; <span class="elsevierStyleItalic">p</span> = 0.006) at week 16 (4.25 <span class="elsevierStyleItalic">vs</span> 0.83; <span class="elsevierStyleItalic">p</span> = 0.017) and week 24 (3.43 <span class="elsevierStyleItalic">vs</span> 0; <span class="elsevierStyleItalic">p</span> = 0.039), and in the FC values at week 4 (1787.4 <span class="elsevierStyleItalic">vs</span> 841; <span class="elsevierStyleItalic">p</span> = 0.028) and week 24 (853.17 <span class="elsevierStyleItalic">vs</span> 16; <span class="elsevierStyleItalic">p</span> = 0.02). No differences were found in the mean baseline values of albumin, C-reactive protein and endoscopic Mayo score between the two groups (failure to ≥2 biological drugs vs failure to one biological drug/bio-naïve): 4.37 <span class="elsevierStyleItalic">vs</span> 4.37 g/dl, <span class="elsevierStyleItalic">p</span> = 0.881; 6.43 <span class="elsevierStyleItalic">vs</span> 5.04 mg/l, <span class="elsevierStyleItalic">p</span> = 0.861 and 2.67 <span class="elsevierStyleItalic">vs</span> 2.00, <span class="elsevierStyleItalic">p</span> = 0.157 respectively.</p><p id="par0075" class="elsevierStylePara elsevierViewall">These data suggest that the decrease in the inflammatory load of naïve patients or patients with failure to a single biological drug occurs more rapidly than in subjects with failure to more than two biological drugs. Therefore, perhaps initiating ustekinumab earlier in the therapeutic pyramid would achieve better remission outcomes.</p><p id="par0080" class="elsevierStylePara elsevierViewall">Six patients (37.5%) had joint manifestations (5 peripheral arthritis, 1 ankylosing spondylitis) which improved in 83.3% according to the overall assessment by Rheumatology.</p><p id="par0085" class="elsevierStylePara elsevierViewall">In our series, none of the patients had a colectomy or had to go to Accident and Emergency or be hospitalised. There was one adverse effect (<span class="elsevierStyleItalic">de novo</span> arthritis) which made it necessary to discontinue the drug.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conclusions</span><p id="par0090" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0095" class="elsevierStylePara elsevierViewall">Ustekinumab is an effective therapeutic option in achieving and maintaining long-term clinical and biological remission in patients with ulcerative colitis, both in those with failure to two or more therapeutic lines and in early lines (bio-naïve and failure to one biological drug).</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0100" class="elsevierStylePara elsevierViewall">Biological remission was achieved in approximately half of the patients and the decrease in FC was particularly evident after week 16.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0105" class="elsevierStylePara elsevierViewall">Treatment optimisation due to loss of, or partial, response is effective in achieving clinical remission, but less effective in achieving biological remission.</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">-</span><p id="par0110" class="elsevierStylePara elsevierViewall">Ustekinumab may be effective in the synergistic treatment of mainly peripheral joint manifestations, although further studies are needed.</p></li></ul></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Funding</span><p id="par0115" class="elsevierStylePara elsevierViewall">The study received no funding.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflicts of interest</span><p id="par0120" class="elsevierStylePara elsevierViewall">None.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conclusions" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Funding" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Conflicts of interest" ] 3 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Age (years), mean (SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49.74 (17.04) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Time since onset of the disease (years), mean (SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.96 (9.87) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Baseline partial Mayo score, mean (SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.75 (2.08) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Gender, <span class="elsevierStyleItalic">n</span> (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Male</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 (56.30) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Female</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (43.80) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Extension of the UC, n (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">E1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (18.80) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">E2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (66.80) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">E3</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (12.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Extraintestinal signs, <span class="elsevierStyleItalic">n</span> (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Yes</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (37.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">No</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (62.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Baseline Mayo endoscopic score, <span class="elsevierStyleItalic">n</span> (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">1</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (10.00) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (40.00) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">3</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (50.00) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Previous biological therapy, <span class="elsevierStyleItalic">n</span> (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Two or more biologicals</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 (56.25) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Two anti-TNF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (12.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>One anti-TNF + vedolizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (6.25) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Two or more anti-TNF + vedolizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (18.75) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Two or more anti-TNF + vedolizumab + tofacitinib \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (12.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">One biological</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (37.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Naïve to biologicals</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (6.25) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Maintenance dose, n (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">90 mg sc every 4 weeks</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (37.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">130 mg iv every 4 weeks</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (31.25) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">90 mg sc every 8 weeks</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (18.75) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">90 mg sc every 12 weeks</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (12.50) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3334584.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Baseline characteristics of the patients and the ulcerative colitis (<span class="elsevierStyleItalic">N</span> = 16).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Chaparro" 1 => "A. Garre" 2 => "M. Iborra" 3 => "M. Sierra-Ausín" 4 => "M. Barreiro-de Acosta" 5 => "A. Fernández-Clotet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ecco-jcc/jjab070" "Revista" => array:6 [ "tituloSerie" => "J Crohns Colitis" "fecha" => "2021" "volumen" => "15" "paginaInicial" => "1846" "paginaFinal" => "1851" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33860795" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: A GETAID cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Fumery" 1 => "J. Filippi" 2 => "V. Abitbol" 3 => "A. Biron" 4 => "D. Laharie" 5 => "M. Serrero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/apt.16544" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2021" "volumen" => "54" "paginaInicial" => "944" "paginaFinal" => "951" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34296456" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.J. Hong" 1 => "N. Krugliak Cleveland" 2 => "S. Akiyama" 3 => "S. Zullow" 4 => "Y. Yi" 5 => "S.R. Shaffer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/crocol/otab002" "Revista" => array:6 [ "tituloSerie" => "Crohns Colitis 360" "fecha" => "2021" "volumen" => "3" "paginaInicial" => "1" "paginaFinal" => "8" "itemHostRev" => array:3 [ "pii" => "S0210569117303674" "estado" => "S300" "issn" => "02105691" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "P383 Ustekinumab as an opportunity for refractory ulcerative colitis patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Iborra" 1 => "C. Soutullo" 2 => "M. Gimeno" 3 => "G. Bastida" 4 => "M. Aguas" 5 => "E. Cerrillo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ecco-jcc/jjab232.510" "Revista" => array:6 [ "tituloSerie" => "J Crohns Colitis" "fecha" => "2022" "volumen" => "16" "numero" => "Suppl 1" "paginaInicial" => "i383" "paginaFinal" => "i384" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/24443824/0000004600000005/v2_202311101339/S2444382423000950/v2_202311101339/en/main.assets" "Apartado" => array:4 [ "identificador" => "77930" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letter" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24443824/0000004600000005/v2_202311101339/S2444382423000950/v2_202311101339/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423000950?idApp=UINPBA00004N" ]
Journal Information
Vol. 46. Issue 5.
Pages 377-379 (May 2023)
Share
Download PDF
More article options
Vol. 46. Issue 5.
Pages 377-379 (May 2023)
Scientific letter
Efficacy, persistence and optimization of ustekinumab in ulcerative colitis: Clinical practice data
Eficacia, persistencia y optimización de ustekinumab en colitis ulcerosa: datos de práctica clínica
Visits
1
This item has received
Article information
These are the options to access the full texts of the publication Gastroenterología y Hepatología (English Edition)
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail